NOCIL Ltd

LTIP grant details

• NRC approved grant of 1,04,960 PRSUs on 23 Sep 2026.
• Pricing: Rs 10 face value; NRC may set price within face to market price.
• PRSUs vest three years from grant date.
• Exercise period begins five years from grant date.
• Total PRSUs granted: 1,04,960 under LTIP 2024.
• Scheme complies with SEBI SBEB Regulations 2021.
• LTIP approved by shareholders at 62nd AGM on 8 Aug 2024.
• LTIP cap: up to 85,00,000 ESOPs/PRSUs.
• No PRSUs exercised yet.

NOCIL Limited — Trading window closed from September 30, 2026 until the conclusion of 48 hours after the declaration of unaudited quarterly and half-year results for the period ended September 30, 2026

Meeting Details

• Date and time: 28 September 2026, 2:00 PM onwards.
• Nature of meeting: 1x1 / Group meeting.
• Organiser: Prabhudas Lilladher.
• Location: Mumbai.
• Purpose: discussions based on publicly available information.

Clarification on volume spurt

• Company states it is in compliance with SEBI LODR regulations.
• No undisclosed price-sensitive information or impending corporate action at present.
• Will promptly inform exchanges of all material events or information as required.

Statutory auditor appointment

• NOCIL Board approves Deloitte Haskins & Sells LLP as statutory auditors for five years.
• Term from conclusion of the 65th AGM (Jul-Aug 2027) to conclusion of the 70th AGM (FY 2031-32).
• Appointment subject to approval by Members at the 65th AGM.
• Kalyaniwalla & Mistry LLP will continue until the end of the 65th AGM.

Financial Performance

• Q1 FY27 net revenue Rs 403 crores, up 20% YoY.
• Volumes grew 9% YoY; sequentially down 3% due to constraints.
• EBITDA Rs 45 crores, up 48% YoY; QoQ up 115%.
• EBITDA margin 11.2% in Q1 FY27.
• Margin rose 210 bps YoY and 480 bps QoQ.
• PBT Rs 37 crores; up 60% YoY, 77% QoQ.
• PAT Rs 28 crores; up 61% YoY, 63% QoQ.

Operations and Volume Trends

• Exports ~33%, domestic ~67% in Q1 FY27.
• TDQ Dahej plant in trial production; samples to customers.
• Rs 130 crore Dahej investment on track amid disruptions.
• Approvals six to eight months; volumes to trickle in Q4, more in Q1 next year.
• R&D and product portfolio expansion targeting positive traction this year.

Guidance and Outlook

• FY27 revenue guidance Rs 1,400–1,600 crores; EBITDA around 10%.
• Full-year volume growth guided around 10%.
• Realizations may moderate; driven by volume, mix, and operating leverage.
• Exports expected to rise toward 40–45% of volumes over time.
• Specialty expansion adds 5–10% to top-line in two years.

Q&A Highlights

• Q1 EBITDA run-rate expected around 10% for FY27; 10% volume growth implied.
• ADD impact on top-line estimated 25–30%; EBITDA impact not yet quantified.
• Exports of ~33% in Q1; target 40–45% over time.
• TDQ approvals six to eight months; first volumes in Q4, larger in Q1.
• INR depreciation not materially affecting volumes; rubber chemicals exports still supported.

Risks and Watchpoints

• Geopolitical uncertainties and logistics disruptions; raw material price volatility.
• Gas supply constraints and higher utilities costs discussed as near-term risks.
• Anti-dumping duties and PILFEX 13 developments; government approvals needed.

Meeting Details

• Analyst/investor conference call; audio recording uploaded on the website.
• Date: intimation dated 4 August 2026; quarter ended 30 June 2026.
• Organizer: NOCIL Limited for the Investors/Analyst call.
• Purpose: discuss operational and financial performance for the quarter ended 30 June 2026.
• Recording available on company website; audio file posted.

Participants

• Key company management participants not disclosed.

Purpose

• Discuss operational and financial performance for the quarter ended 30 June 2026.

Additional Notes

• Audio recording posted on website; no transcript mentioned.